Evidence map›Paper›PMID 34432128›Full record

ArticleJournal of cancer research and clinical oncology2022

Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.

Ta-Chen Huang, Cher-Wei Liang, Yu-I Li, Jhe-Cyuan Guo, Chia-Chi Lin, Ya-Jhen Chen, Ann-Lii Cheng, Chih-Hung Hsu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ta-Chen HuangGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
Cher-Wei LiangDepartment of Pathology, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan.
Yu-I LiDepartment of Pathology, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan.
Jhe-Cyuan GuoDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Chia-Chi LinDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Ya-Jhen ChenGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
Ann-Lii ChengGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.
Chih-Hung HsuGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.ORCID http://orcid.org/0000-0003-0495-973X
National Taiwan University · TWFu Jen Catholic University · TWNational Taiwan University Hospital · TW

Funding

national center of excellence for clinical trial and research NCTRC200909national science council MOST 105-2314-B-002-186-MY3national science council MOST 108-2314-B-002-076-MY3national taiwan university hospital NTUH 110-S5021
6 · The paper itself

Abstract

purposeProgrammed death-ligand 1 (PD-L1) expression may influence the prognosis of patients with localized esophageal cancer. The current study compared the prognostic value of PD-L1 expression between tumor cells and immune cells.

methodsArchival esophageal tumor tissue samples were collected from patients who received paclitaxel and cisplatin-based neoadjuvant chemoradiotherapy (CRT) for locally advanced esophageal squamous cell carcinoma (ESCC) in three prospective phase II trials. PD-L1 expression on tumor and immune cells was examined immunohistochemically by using the SP142 antibody and scored by two independent pathologists. The association of PD-L1 expression with patient's outcomes was analyzed using a log-rank test and Cox regression multivariate analysis.

resultsA total of 100 patients were included. PD-L1 expression on tumor cells was positive (≥ 1%, TC-positive) in 55 patients; PD-L1 expression on immune cells was high (≥ 5%, IC-high) in 30 patients. TC-positive status was associated with poor overall survival (OS) (HR: 1.63, P = 0.035), whereas IC-high status was associated with improved OS (HR: 0.44, P = 0.0024). Multivariate analysis revealed that TC-positive, IC-high, and performance status were independent prognostic factors for progression-free survival and that IC-high and performance status were independent factors for OS. Furthermore, the combination of IC-high and TC-negative status was associated with the optimal OS, whereas that of TC-positive and IC-low status was associated with the worst OS.

conclusionPD-L1 expression on tumor and immune cells may have different prognostic value for patients with locally advanced ESCC receiving neoadjuvant CRT. A combination of these two indexes may further improve the prognostic prediction.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaB7-H1 AntigenChemoradiotherapyHumansNeoadjuvant TherapyPrognosisProspective StudiesB7-H1 AntigenCD274 protein, humanEsophageal squamous cell carcinomaImmune cellsNeoadjuvant chemoradiotherapyPD-L1Prognosis

Identifiers

PMID34432128
PMCPMC11800914
OpenAlexW3175946643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.